SCHEMBL6564874

SCHEMBL6564874

Cc1cc(C(=O)O)ccc1-c1cccc(O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.56
AKR1C2 P52895 2/20 0.56
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA6 P23280 1/20 0.55
CA9 Q16790 1/20 0.55
ESR2 Q92731 2/20 0.54
HSD17B1 P14061 3/20 0.51
RARB P10826 1/20 0.48
CHEK1 O14757 1/20 0.48
EGFR P00533 1/20 0.47
NR1H4 Q96RI1 1/20 0.47
ADH5 P11766 1/20 0.46
CNR2 P34972 1/20 0.46
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HSD17B2 P37059 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31658246 0.90 AKR1C3 (0.61) AKR1C3AKR1C2ESR2RARBNR1H4
SCHEMBL6252539 0.88 AKR1C3 (0.68) AKR1C3AKR1C2RARBNR1H4ADH5
SCHEMBL1787533 0.86 PARP1 (0.56) AKR1C3AKR1C2ESR2HSD17B1CNR2
SCHEMBL122524 0.85 CNR2 (0.57) AKR1C3AKR1C2RARBNR1H4ADH5
SCHEMBL121338 0.84 ESR2 (0.58) AKR1C3AKR1C2ESR2HSD17B1RARB
SCHEMBL29707122 0.84 ESR2 (0.58) AKR1C3AKR1C2ESR2HSD17B1RARB
SCHEMBL26681146 0.83 SLC2A1 (0.52) CA12CA1CA2CA9ESR2
Hydrochloric Acid SCHEMBL5753140 0.83 ESR2 (0.56) AKR1C3AKR1C2ESR2HSD17B1RARB
SCHEMBL28789039 0.83 AKR1C3 (0.55) AKR1C3AKR1C2RARBNR1H4ADH5
SCHEMBL4539558 0.83 AKR1C3 (0.55) AKR1C3AKR1C2RARBNR1H4ADH5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132431-A1 METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-04-25 US disclosed
EP-4279476-A1 METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-22 EP disclosed
EP-1235777-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2004-06-16 EP disclosed
EP-1235777-A2 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2002-09-04 EP disclosed
WO-2001038303-A2 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2001-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132431-A1 METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP MGMT, MCL1, FANCF AKR1C3 225/4885AKR1C2 355/4885CA12 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.